Previously recorded as Essentia Biosystems, Inc. (to 2009)
28 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
17 more records may belong here and await a decision; they are not counted.
The next US patent term in the Revance Therapeutics, Inc. portfolio ends in Dec 2026, and more of its terms end in 2030 (6) than in any other year. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
17
Ending by 2030
Dec 2026
Next term end
20
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Oct 2028 · High confidence
Also notable
Ends Oct 2030 · Low confidence
Also notable
Ends Sep 2035 · High confidence
Also notable
Ends Jan 2032 · High confidence
Also notable
Ends Oct 2027 · High confidence
Also notable
Ends Oct 2033 · High confidence
Also notable
Ends Sep 2031 · High confidence
Also notable
Ends Jan 2027 · High confidence
Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
US 8,926,991
Cited by 34 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
Methods and Systems for Purifying Non-Complexed Botulinum Neurotoxin
US 11,466,262
Cited by 9 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
Albumin-Free Botulinum Toxin Formulations
US 9,340,587
Cited by 36 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
Injectable Botulinum Toxin Formulations
US 9,956,435
Cited by 19 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2032.
Compositions and Methods for Topical Application and Transdermal Delivery of Botulinum Toxins
US 8,398,997
Cited by 26 later US patents, top 25% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Compositions and Methods for Safe Treatment of Rhinitis
US 10,201,594
Cited by 22 later US patents, top 25% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2033.
Extended Length Botulinum Toxin Formulation for Human or Mammalian Use
US 9,066,851
Cited by 24 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
Pharmaceutical Botulinum Toxin Compositions
US 8,241,640
The largest patent family in this portfolio, 7 related applications, renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Aug 27, 2027The maintenance fee for Albumin-Free Botulinum Toxin Formulations (US 11,911,449) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
- 1 fee due Nov 17, 2027The maintenance fee for Albumin-Free Botulinum Toxin Formulations (US 9,340,587) comes due Nov 17, 2027. Unpaid by May 17, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 24, 2026
What they patent
The largest of its 20 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,628,756 | Arginine Heteromers for Topical Administration In force · High confidence | In force | High confidence | |
| US 8,241,640 | Pharmaceutical Botulinum Toxin Compositions In force · High confidence | In force | High confidence | |
| US 8,815,954 | Arginine Heteromers for Topical Administration In force · High confidence | In force | High confidence | |
| US 8,691,769 | Treatment of sinusitis related chronic facial pain and headache with botulinum toxin injections In force · High confidence | In force | High confidence | |
| US 8,398,997 | Compositions and Methods for Topical Application and Transdermal Delivery of Botulinum Toxins In force · High confidence | In force | High confidence | |
| US 8,580,317 | Compositions and Methods for Treating Acne In force · High confidence | In force | High confidence | |
| US 8,926,991 | Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect In force · High confidence | In force | High confidence | |
| US 8,192,979 | Compositions, Methods and Devices for Preparing Less Painful Botulinum Toxin Formulations In force · High confidence | In force | High confidence | |
| US 8,404,249 | Compositions and methods for topical application and transdermal delivery of botulinum toxins In force · High confidence | In force | High confidence | |
| US 9,950,042 | Extended Length Botulinum Toxin Formulation for Human or Mammalian Use In force · High confidence | In force | High confidence |
Also on record, not counted in the 28: 23 patents ended · 13 applications pending · 60 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.